Application of traditional Chinese medicine composition in preparation of drugs for adjuvant therapy of novel coronavirus pneumonia

Abstract

The invention discloses an application of a traditional Chinese medicine composition in preparation of drugs for adjuvant therapy of novel coronavirus pneumonia. The traditional Chinese medicine composition comprises the raw materials: radix puerariae, radix scutellariae, rhizoma coptidis and radix glycyrrhizae preparata. Pneumonia patients infected by novel coronavirus mainly show fever, cough, dyspnea and the like, and part of the pneumonia patients can also show digestive system symptoms such as poor appetite, nausea, emesis, diarrhea and the like. Clinical experiments find that the traditional Chinese medicine composition has a good adjuvant therapy effect on novel coronavirus pneumonia in combination with conventional therapy, can quickly stabilize the condition of an illness, and particularly has a more obvious effect on improving cough, chest distress, nausea, vomiting, loose stool and the like. The average antipyretic time is 3 days, the average nucleic acid negative conversiontime is 8 days, and the clinical cure rate is 100%. The traditional Chinese medicine composition disclosed by the invention can block the conversion of mild and common pneumonia patients into severeand critical pneumonia patients; clinical symptoms of patients can be actively improved; lung inflammatory absorption can be well promoted; safe and reliable use is achieved.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicines, and in particular relates to the application of traditional Chinese medicine compositions in the preparation of medicines for the auxiliary treatment of novel coronavirus pneumonia. Background technique [0002] Since 2019, many cases of novel coronavirus (COVID-19) pneumonia have been discovered around the world. The epidemic is urgent and the situation is severe. At present, there are no confirmed effective targeted drugs and vaccines. There is no breakthrough in the research and development of antiviral drugs. There are certain difficulties in the prevention, control and treatment of new coronavirus pneumonia. On February 8, 2020, the National Health Commission issued the "Pneumonia Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 5 Revised Version)", and required all relevant medical institutions to actively play the role of traditional Chinese medicine ...

AI Technical Summary

Problems solved by technology

The epidemic is urgent and the situation is grim. At present, there are no confirmed effective targeted drugs and vaccines. There is no breakthrough in

Images